公开(公告)号：EP2359850A1

公开(公告)日：2011-08-24

申请号：EP09827196.8

申请日：2009-11-19

申请人： Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros

发明人： PEREZ MARTIN, Oliver Germán ,  GONZALEZ AZNAR, Elizabeth ,  ROMEU ALVAREZ, Belkis ,  DEL CAMPO ALONSO, Judith Mónica ,  ACEVEDO GROGUES, Reinaldo ,  LASTRE GONZALEZ, Miriam de San Juan Bosco ,  ZAYAS VIGNIER, Caridad ,  CUELLO PEREZ, Maribel ,  CABRERA BLANCO, Osmir ,  NUÑEZ GUTIERREZ, Niurys ,  BALBOA GONZALEZ, Julio Antonio

IPC分类号： A61K39/095 ,  A61K9/127 ,  A61P37/04

CPC分类号： A61K39/095 ,  A61K39/0017 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K2039/542 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/55555 ,  A61K2039/55594 ,  A61K2039/70

摘要： The invention is related to the field of vaccines. The technical objective is to obtain novel unitemporal therapeutic and prophylactic vaccines (single time vaccination strategy) using simultaneously one or more mucosal doses and one parenteral dose where the use of potent mucosal adjuvants are essential, preferable the Cochleate (AFCo1, Adjuvant Finlay Cochleate 1). The incorporation or co-administration by parenteral and mucosal routes of non-related PL antigens (heterologous), and/or the additional use of delivery systems like Aluminum, Chitosan or oil/water emulsions by parenteral application is also included in this invention. The induction of cellular immune responses than including systemic specific IgG and secretory specific IgA is obtained with at least two simultaneously doses. So, this unitemporal strategy is applicable to obtaining new unique or multiples vaccines (several mucosal vaccine antigens with the corresponding parenteral combine vaccine) in the pharmaceutical industry which permit to increase vaccine coverage and reduce the time-cost of vaccine campaigns.

摘要翻译： 本发明涉及疫苗领域。 技术目标是使用同时一种或多种粘膜剂量和一种肠胃外剂量获得新颖的单时间治疗和预防性疫苗（单次接种疫苗策略），其中使用有效粘膜佐剂是必需的，优选耳蜗（AFCo1，辅助Finlay Cochleate 1） 。 通过胃肠外和粘膜途径引入或共同施用非相关PL抗原（异源），和/或通过肠胃外应用附加使用递送系统如铝，壳聚糖或油/水乳剂也包括在本发明中。 使用至少两个同时剂量获得比包括全身特异性IgG和分泌特异性IgA的细胞免疫应答的诱导。 因此，这种单时间策略适用于在制药行业获得新的独特或多重疫苗（几种具有相应的肠胃外联合疫苗的粘膜疫苗抗原），这可以增加疫苗覆盖面积，并减少疫苗运动的时间成本。